Coherus Oncology, Inc.

Aeon Biopharma, which is working on developing a biosimilar version of Botox (onabotulinumtoxinA) in the US, has looked to rival developer Revance Therapeutics to recruit its new chief executive. Aeon

Akeso has garnered a regulatory nod for penpulimab from the US Food and Drug Administration, making the agent the second PD-1 checkpoint inhibitor originating from a Chinese drug maker in the US marke

It’s official: Coherus BioSciences is finally out of the biosimilars business. The company has marked the end of a long road to transition from being a biosimilars player to an innovative immuno-oncol

Sandoz management has set out more details of how it intends to reposition in the US market the Cimerli (ranibizumab-eqrn) biosimilar to Lucentis that it licenses from Formycon. In mid-February, Germa